TYK2 and interstitial lung disease: Therapeutic pipelines will likely expand through JAK/TYK2 inhibitors for IFN-high endotypes, FcRn inhibitors, and B-cell or co-stimulation blockade for refractory disease, and trials stratified by antibody and ILD status.